Halozyme Therapeutics Inc
NASDAQ:HALO

Watchlist Manager
Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc
NASDAQ:HALO
Watchlist
Price: 53.31 USD -4.19% Market Closed
Market Cap: 6.6B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+35%
Revenue
Forecast
+19%
Operating Income
Forecast
+26%
Net Income
Forecast
+34%

Wall Street
Price Targets

HALO Price Targets Summary
Halozyme Therapeutics Inc

Wall Street analysts forecast HALO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HALO is 71.98 USD with a low forecast of 62.62 USD and a high forecast of 82.95 USD.

HALO Lowest Forecast
Wall Street Target
62.62 USD
17% Upside
HALO Average Forecast
Wall Street Target
71.98 USD
35% Upside
HALO Highest Forecast
Wall Street Target
82.95 USD
56% Upside
Lowest
Price Target
62.62 USD
17% Upside
Average
Price Target
71.98 USD
35% Upside
Highest
Price Target
82.95 USD
56% Upside
Halozyme Therapeutics Inc Competitors:
Price Targets
302440
SK Bioscience Co Ltd
13% Downside
ANAB
AnaptysBio Inc
78% Upside
OCX
OncoCyte Corp
80% Upside
OPK
OPKO Health Inc
128% Upside
302440
SK Bioscience Co Ltd
13% Downside
ANAB
AnaptysBio Inc
78% Upside
OCX
OncoCyte Corp
80% Upside
OPK
OPKO Health Inc
128% Upside
NTRA
Natera Inc
28% Upside
NIOX
Niox Group PLC
14% Upside
ONCO
Oncopeptides AB
279% Upside
300896
Imeik Technology Development Co Ltd
29% Upside

Revenue
Forecast

Revenue Estimate
Halozyme Therapeutics Inc

For the last 8 years the compound annual growth rate for Halozyme Therapeutics Inc's revenue is 27%. The projected CAGR for the next 3 years is 19%.

27%
Past Growth
19%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Halozyme Therapeutics Inc

The compound annual growth rate of Halozyme Therapeutics Inc's operating income for the next 3 years is 26%.

N/A
Past Growth
26%
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Halozyme Therapeutics Inc

The compound annual growth rate of Halozyme Therapeutics Inc's net income for the next 3 years is 34%.

N/A
Past Growth
34%
Estimated Growth
Estimates Accuracy
10%
Average Beat
What are analyst estimates?

See Also

Summary
HALO intrinsic value, competitors valuation, and company profile.
DCF Valuation
HALO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HALO stock valuation using valuation multiples.
Wall Street Estimates
HALO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HALO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HALO's stock price target?
Price Target
71.98 USD

According to Wall Street analysts, the average 1-year price target for HALO is 71.98 USD with a low forecast of 62.62 USD and a high forecast of 82.95 USD.

What is Halozyme Therapeutics Inc's Revenue forecast?
Projected CAGR
19%

For the last 8 years the compound annual growth rate for Halozyme Therapeutics Inc's revenue is 27%. The projected CAGR for the next 3 years is 19%.

What is Halozyme Therapeutics Inc's Operating Income forecast?
Projected CAGR
26%

The compound annual growth rate of Halozyme Therapeutics Inc's operating income for the next 3 years is 26%.

What is Halozyme Therapeutics Inc's Net Income forecast?
Projected CAGR
34%

The compound annual growth rate of Halozyme Therapeutics Inc's net income for the next 3 years is 34%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 259,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.